Integrin-Linked Kinase Suppression Reduces SPARC's Effect on Intraocular Pressure and Extracellular Matrix
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.10.53 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by Charles W Guo and 12 co-authors. Institution: Department of Ophthalmology and Visual Sciences, Case Western Reserve University, School of Medicine, Cleveland, Ohio, United States. Major MEDLINE topics: Osteonectin, Intraocular Pressure, Protein Serine-Threonine Kinases, Trabecular Meshwork. 54 references. The full text is freely available (open access, CC BY 4.0). Funded by: NEI NIH HHS.
Abstract (original language)
Purpose
The molecular pathway for increased outflow resistance in the trabecular meshwork (TM) remains unknown. Secreted protein, acidic and rich in cysteine (SPARC) has been shown to regulate intraocular pressure (IOP) correlating to extracellular matrix (ECM) alterations. In other tissues, SPARC binds integrin-linked kinase (ILK) and regulates ECM organization through signaling cascades. We hypothesized SPARC regulates ECM proteins partly through ILK in the TM.
Methods
Adenovirus carrying cDNA of human SPARC (Ad.SPARC) was used to overexpress SPARC and a lentivirus carrying short-hairpin RNA (shRNA) targeting human ILK (shILK) was used to inhibit ILK in live mice, primary human TM cells, and perfused human cadaveric anterior segments. IOP was measured in mice and human anterior segments. Selected ECM proteins were analyzed by immunoblotting and immunostaining.
Results
SPARC overexpression elevated IOP 1.87 ± 0.50 millimeters of mercury (mm Hg; P = 0.009, n = 15) in mice. Coinfection with ILK inhibition reduced IOP by 3.64 ± 0.57 mm Hg (P < 0.001, n = 15) and histologically reduced ECM proteins compared to SPARC overexpression. In human anterior segments, SPARC overexpression elevated IOP 2.10 ± 0.25-fold (P = 0.021, n = 4), whereas addition of shILK attenuated SPARC's effect and decreased IOP 0.61 ± 0.31-fold (P = 0.015, n = 4). In human TM cells, Ad.SPARC infection elevated levels of SPARC and laminin. Coinfection with shILK reduced levels of ILK, collagen I, collagen VI, and laminin.
Conclusions
ILK inhibition attenuated the effects of SPARC overexpression on IOP and ECM proteins, suggesting ILK signaling may contribute to the pathway of SPARC-mediated regulation of ECM homeostasis in TM. Future studies evaluating the downstream transcription factors may provide an elucidated pathway for POAG pathogenesis.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Ophthalmology and Visual Sciences, Case Western Reserve University, School of Medicine, Cleveland, Ohio, United States.
- Department of Ophthalmology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States.
- Case Comprehensive Cancer Center, Cleveland, Ohio, United States.
Funding
- NEI NIH HHS
Cite
APA
Guo, C. W., Birrell, S., Baillargeon, S., Koster, K., Jeppesen, B., Zheng, Y., Castillejos, A., Murali, A., Kang, M. H., Scott-McKean, J., Lee, H., Matsuyama, S., & Rhee, D. J. (2026). Integrin-Linked Kinase Suppression Reduces SPARC's Effect on Intraocular Pressure and Extracellular Matrix. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.10.53
Vancouver
Guo CW, Birrell S, Baillargeon S, Koster K, Jeppesen B, Zheng Y, et al. Integrin-Linked Kinase Suppression Reduces SPARC's Effect on Intraocular Pressure and Extracellular Matrix. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.10.53
BibTeX
@article{Guo2026,
author = {Guo, Charles W and Birrell, Seth and Baillargeon, Sophie and Koster, Karl and Jeppesen, Bridger and Zheng, Yuxi and Castillejos, Alexandra and Murali, Archana and Kang, Min Hyung and Scott-McKean, Jonah and Lee, Hyunpil and Matsuyama, Shigemi and Rhee, Douglas J},
title = {Integrin-Linked Kinase Suppression Reduces SPARC's Effect on Intraocular Pressure and Extracellular Matrix},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.10.53}
}
EUVIMED